Youngen, based in Beijing, is a biotechnology company pioneering the development of next-generation siRNA drugs to silence specific mRNAs and reduce the production of proteins that cause diseases. Youngen has been dedicated to bringing RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and general, impacting millions of people and families around the world. Leveraging cutting-edge technological platforms, we build globally competitive diversified product pipelines with first-in-class and best-in-class potentials. We're exploring many therapeutic areas to bring more treatment options to the patients with metabolic and cardiovascular diseases, immune-mediated diseases, and neurological disorders.
To become a global leader in the prevention and treatment of chronic and rare diseases with innovative siRNA drugs.
Pioneer and Promote technological progress in RNA interference , and benefit human health
Innovation, Breakthrough, Cooperation, Win-Win
Promote the development of the global RNAi based therapeutics industry
